Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00224055
Status:
COMPLETED
Last Update Posted:
2012-03-29
First Post:
2005-09-13
Brief Title:
Effect of Ferrlecit Versus Oral Iron on Iron Deficient Chronic Kidney Disease CKD Patients
Sponsor:
Watson Pharmaceuticals
Organization:
Watson Pharmaceuticals
Study Overview
Official Title:
A Randomized Controlled Open-label Study of the Safety and Efficacy of Ferrlecit vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study compares the effect of Ferrlecit a form of intravenous iron to ferrous sulfate a form of oral iron in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents hormones that stimulate the bone marrow to make more red blood cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None